Scotland · NHS Scotland MSAN
Naloxegol (Moventig®) 12.5mg and 25mg tablets
MSAN(2024)17 · Level 2 · issued 25 Apr 2024
What the notice states
The supply position for each affected product, as recorded in the notice — read the full signed PDF above for the clinical advice and actions.
| Product | Position | Resupply |
|---|---|---|
| 1. Naloxegol (Moventig®) 12.5mg tablets are out of stock until early August 2024. | Out of stock | early August 2024 |
| 2. Naloxegol (Moventig®) 25mg tablets are out of stock until the end of April 2024. | Out of stock | the end of April 2024 |
| 3. Naldemedine (Rizmoic®) 200 micrograms tablets remain available and can support increased | Available | — |
| film-coated and unscored; no data are available on halving them, and this manipulation would | Available | — |
| Registration for access to the website is available to UK healthcare professionals and | Available | — |
Provenance
Where this record's bytes came from and when they entered the record. The same fields ship with every API record (/api), so a citation can be checked against the capture. Internet-Archive recoveries are dated by the Archive's capture, never ours.
scot:msan:2024:17
- Recorded
- 13 Aug 2026 22:03 UTC
- Capture route
- Captured first-hand by ShortageSignal's scheduled check
- Read from
- NHS Scotland Medicine Supply Alert Notice (PDF)
- Captured at
- 13 Aug 2026 22:03 UTC
- Content hash
954ed56f8f7aa3a72da697a38f44f0213289a2bec0167ba0e305230e43ca445asha256 of the captured bytes — proves what was captured, not that the source was correct- Source document
- https://www.publications.scot.nhs.uk/files/msan-2024-17.pdf ↗
From the NHS Scotland notice PDF (linked above); dates and “valid until” text are as stated, fuzzy wording kept as written. Scotland is covered separately from England — see methodology. Not an official NHS service, and not clinical advice — follow the guidance issued to your pharmacy.